CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for...
HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 /PRNewswire/ -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment...
View ArticleJanssen to Showcase Growing Portfolio with More Than 40 Data Presentations at...
(Source: Johnson & Johnson) Note: This release corresponds to ASH abstracts 29, 55, 57, 267, 377, 431, 469, 470, 495, 507, 508, 626, 699, 747, 833, 875, 894 RARITAN, NJ, November 5, 2015 - At the...
View ArticleKey Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute...
THOUSAND OAKS, Calif., Nov. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis® (carfilzomib)...
View ArticleKey Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute...
THOUSAND OAKS, Calif., Nov. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a number of important abstracts from the Company's oncology portfolio, including Kyprolis® (carfilzomib) for...
View ArticleKaryopharm to Present Data on Oncology Pipeline at American Society of...
(Source: Karyopharm Therapeutics Inc) NEWTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 17...
View ArticleAffimed to Present Data on NK- and T-Cell Engagers at ASH (Affimed NV)
(Source: Affimed NV) 21a0a43f-3cf1-4765-97f5-1cced1f376d4.pdf FOR IMMEDIATE RELEASE Affimed to Present Data on NK- and T-Cell Engagers at ASH Heidelberg, Germany, November 5, 2015 - Affimed N.V....
View ArticleXencor to Present at Credit Suisse 24th Annual Healthcare Conference
MONROVIA, Calif., Nov. 4, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports Third Quarter 2015 Financial Results and Pipeline Update
, Nov. 3, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biotechnology company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticlePreclinical Data of Xencor's XmAb Bispecific Technology to be Presented at...
MONROVIA, Calif., Nov. 5, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleMEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune...
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today highlighted the application of...
View ArticleLycera Announces Progress in Immuno-Oncology Program to be Presented at...
NEW YORK and ANN ARBOR, Mich., Nov. 3, 2015 /PRNewswire/ -- Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that research...
View ArticleGenmab Achieves $3 Million Milestone Payment in DuoBody Platform...
Genmab achieves $3 million milestone payment in DuoBody(r) collaboration with Janssen COPENHAGEN, Denmark, Oct. 25, 2015 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today it has achieved...
View ArticleDelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising...
VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 11, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the...
View ArticleIMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST QUARTER FISCAL...
(Source: Immunomedics Inc) Microsoft Word - IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST QUARTER FISCAL 2016 FINANCIAL RESULTS IMMUNOMEDICS,® INC. 300 The American Road, Morris Plains,...
View ArticleIMMUNOMEDICS REPORTS IMPROVED PROGRESSION-FREE SURVIVAL RESULTS WITH...
(Source: Immunomedics Inc) Microsoft Word - IMMUNOMEDICS REPORTS IMPROVED PFS RESULTS WITH IMMU-132 IN TNBC IMMUNOMEDICS,® INC. 300 The American Road, Morris Plains, New Jersey 07950 ¤ (973) 605-8200 ¤...
View ArticleSunesis Pharmaceuticals Presents Preclinical Data From Its BTK and PDK1...
(Source: Sunesis Pharmaceuticals Inc) SOUTH SAN FRANCISCO, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that two posters detailing preclinical...
View ArticleImmunomedics Reports Improved Progression-Free Survival Results With...
BOSTON, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that patients with metastatic triple-negative breast cancer (TNBC) lived for a median of seven months without...
View ArticleOpexa Therapeutics Announces Supportive Preclinical Study Results for its...
(Source: Opexa Therapeutics Inc) THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc.(NASDAQ: OPXA), a biopharmaceutical company developing personalized otherapies for autoimmune disorders...
View ArticleMorphotek®, Inc. Presents Preclinical Findings At ESGO 19 On The Potential...
EXTON, Pa., Oct. 26, 2015 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor...
View ArticleIMMUNOMEDICS ANNOUNCES SACITUZUMAB GOVITECAN IS SYNERGISTIC WITH...
(Source: Immunomedics Inc) Microsoft Word - IMMUNOMEDICS ANNOUNCES IMMU-132 IS SYNERGISTIC WITH CHEMOTHERAPEUTICS IN TNBC IMMUNOMEDICS,® INC. 300 The American Road, Morris Plains, New Jersey 07950 ¤...
View Article